JNJ Sep 2024 155.000 put
| Previous close | 8.70 |
| Open | 8.70 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 155.00 |
| Expiry date | 2024-09-20 |
| Day's range | 8.70 - 8.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.01k |
GuruFocus.comBeyond the Balance Sheet: What SWOT Reveals About Shockwave Medical Inc (SWAV)
Insightful Analysis of Shockwave Medical's Position in the Cardiovascular Device Market
BenzingaJohnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. These data were featured at the 2024 American Urological Association (AUA) Annual Meeting. Results featured updated data from Cohort 1 (C1),
GlobeNewswireShockwave Medical Reports First Quarter 2024 Financial Results
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of ou
